• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

25-64 岁美国成年人糖尿病诊断前 10 年和后 10 年的过度医疗支出轨迹,2001-2013 年。

Trajectory of Excess Medical Expenditures 10 Years Before and After Diabetes Diagnosis Among U.S. Adults Aged 25-64 Years, 2001-2013.

机构信息

Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA

Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.

出版信息

Diabetes Care. 2019 Jan;42(1):62-68. doi: 10.2337/dc17-2683. Epub 2018 Nov 19.

DOI:10.2337/dc17-2683
PMID:30455325
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6393199/
Abstract

OBJECTIVE

We assessed the excess medical expenditures for adults newly diagnosed with diabetes, for up to 10 years before and after diabetes diagnosis.

RESEARCH DESIGN AND METHODS

Using the 2001-2013 MarketScan data, we identified people with newly diagnosed diabetes among adults aged 25-64 years (diabetes cohort) and matched them with people who did not have diagnosed diabetes (control cohort) using 1:1 propensity score matching. We followed these two cohorts up to ±10 years from the index date, with annual matched cohort sizes ranging from 3,922 to 39,726 individuals. We estimated the yearly and cumulative excess medical expenditures of the diabetes cohorts before and after the diagnosis of diabetes.

RESULTS

The per capita annual total excess medical expenditure for the diabetes cohort was higher for the entire 10 years prior to their index date, ranging between $1,043 in year -10 and $4,492 in year -1. Excess expenditure spiked in year 1 ($8,109), declined in year 2, and then increased steadily, ranging from $4,261 to $6,162 in years 2-10. The cumulative excess expenditure for the diabetes cohort during the entire 20 years of follow-up was $69,177 ($18,732 before and $50,445 after diagnosis).

CONCLUSIONS

People diagnosed with diabetes had higher medical expenditures compared with their counterparts, not only after diagnosis but also up to 10 years prior to diagnosis. Managing risk factors for type 2 diabetes and cardiovascular disease before diagnosis, and for diabetes-related complications after diagnosis, could alleviate medical expenditure in people with diabetes.

摘要

目的

我们评估了成年人新诊断为糖尿病前后长达 10 年的额外医疗支出。

研究设计和方法

利用 2001-2013 年 MarketScan 数据,我们在 25-64 岁成年人中识别出新诊断为糖尿病的患者(糖尿病队列),并使用 1:1 倾向评分匹配将他们与未诊断出糖尿病的患者(对照组)进行匹配。我们对这两个队列进行了最长 10 年的随访,每年匹配队列的人数从 3922 人到 39726 人不等。我们估计了糖尿病队列在诊断前和诊断后每年和累计的额外医疗支出。

结果

糖尿病队列在其索引日期前的整个 10 年内,人均年总额外医疗支出较高,在第-10 年为 1043 美元,在第-1 年为 4492 美元。在第 1 年(8109 美元)支出急剧增加,第 2 年下降,然后稳步增加,在第 2-10 年在 4261 美元至 6162 美元之间。在整个 20 年的随访期间,糖尿病队列的累计超额支出为 69177 美元(诊断前为 18732 美元,诊断后为 50445 美元)。

结论

与对照组相比,诊断出糖尿病的患者不仅在诊断后,而且在诊断前长达 10 年内的医疗支出更高。在诊断前管理 2 型糖尿病和心血管疾病的风险因素,以及诊断后管理糖尿病相关并发症,可以减轻糖尿病患者的医疗支出。

相似文献

1
Trajectory of Excess Medical Expenditures 10 Years Before and After Diabetes Diagnosis Among U.S. Adults Aged 25-64 Years, 2001-2013.25-64 岁美国成年人糖尿病诊断前 10 年和后 10 年的过度医疗支出轨迹,2001-2013 年。
Diabetes Care. 2019 Jan;42(1):62-68. doi: 10.2337/dc17-2683. Epub 2018 Nov 19.
2
Medical expenditures associated with major depressive disorder among privately insured working-age adults with diagnosed diabetes in the United States, 2008.美国有诊断糖尿病的私营保险工作年龄成年人中,与重度抑郁症相关的医疗支出,2008 年。
Diabetes Res Clin Pract. 2013 Apr;100(1):102-10. doi: 10.1016/j.diabres.2013.02.002. Epub 2013 Mar 13.
3
Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.新诊断 2 型糖尿病患者使用胰岛素治疗的资源利用和成本。
J Manag Care Spec Pharm. 2015 Mar;21(3):220-8a. doi: 10.18553/jmcp.2015.21.3.220.
4
Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study.评估商业健康计划中质量衡量标准遵守情况的定义与经济结果之间的关系:一项回顾性糖尿病队列研究。
J Manag Care Spec Pharm. 2021 Jan;27(1):64-72. doi: 10.18553/jmcp.2021.27.1.064.
5
Medical expenditure trajectory and HbA1c progression prior to and after clinical diagnosis of type 2 diabetes in a commercially insured population in the USA.美国商业保险人群中临床诊断 2 型糖尿病前后的医疗支出轨迹和 HbA1c 进展情况。
BMJ Open Diabetes Res Care. 2023 Nov;11(6). doi: 10.1136/bmjdrc-2023-003397.
6
Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.V-Go 与多次每日注射对 2 型糖尿病患者血糖控制、胰岛素使用和糖尿病药物费用的影响。
J Manag Care Spec Pharm. 2019 Oct;25(10):1111-1123. doi: 10.18553/jmcp.2019.25.10.1111.
7
Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.2 型糖尿病患者坚持基础-餐时胰岛素治疗对临床和经济结局的影响:一项回顾性理赔数据库研究。
J Manag Care Spec Pharm. 2019 Dec;25(12):1420-1431. doi: 10.18553/jmcp.2019.19097. Epub 2019 Sep 24.
8
Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting.美国商业医保支付环境下糖尿病儿童和成人并发症的直接医疗费用。
Appl Health Econ Health Policy. 2014 Apr;12(2):219-30. doi: 10.1007/s40258-014-0086-9.
9
Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.美国2型糖尿病患者起始治疗后的基础胰岛素持续性、相关因素及治疗结果
Curr Med Res Opin. 2016;32(4):669-80. doi: 10.1185/03007995.2015.1135789. Epub 2016 Jan 13.
10
Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.在医疗补助按服务收费人群中,使用吡格列酮或罗格列酮起始治疗的依从性患者与使用胰岛素的患者的药物利用情况及成本比较
J Manag Care Pharm. 2006 Mar;12(2):121-9. doi: 10.18553/jmcp.2006.12.2.121.

引用本文的文献

1
2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.《2025年心脏病和中风统计数据:美国心脏协会关于美国和全球数据的报告》
Circulation. 2025 Feb 25;151(8):e41-e660. doi: 10.1161/CIR.0000000000001303. Epub 2025 Jan 27.
2
Instrumental variables in the cost of illness featuring type 2 diabetes.2型糖尿病疾病成本中的工具变量
Health Serv Res. 2025 Jun;60(3):e14412. doi: 10.1111/1475-6773.14412. Epub 2024 Nov 26.
3
Chronic Physical and Mental Health Conditions Associated With Employment Status in Veterans.

本文引用的文献

1
Economic Costs of Diabetes in the U.S. in 2017.2017 年美国糖尿病的经济成本。
Diabetes Care. 2018 May;41(5):917-928. doi: 10.2337/dci18-0007. Epub 2018 Mar 22.
2
Impact of diabetes on healthcare costs in a population-based cohort: a cost analysis.基于人群队列研究的糖尿病对医疗费用的影响:一项成本分析。
Diabet Med. 2016 Mar;33(3):395-403. doi: 10.1111/dme.12858. Epub 2015 Aug 19.
3
Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting.
退伍军人中与就业状况相关的慢性身心健康状况
AJPM Focus. 2024 May 16;3(4):100242. doi: 10.1016/j.focus.2024.100242. eCollection 2024 Aug.
4
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.2024 年心脏病与中风统计数据:美国心脏协会发布的美国和全球数据报告。
Circulation. 2024 Feb 20;149(8):e347-e913. doi: 10.1161/CIR.0000000000001209. Epub 2024 Jan 24.
5
Medical expenditure trajectory and HbA1c progression prior to and after clinical diagnosis of type 2 diabetes in a commercially insured population in the USA.美国商业保险人群中临床诊断 2 型糖尿病前后的医疗支出轨迹和 HbA1c 进展情况。
BMJ Open Diabetes Res Care. 2023 Nov;11(6). doi: 10.1136/bmjdrc-2023-003397.
6
Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases.与心肾代谢疾病的发生和联合相关的医疗保健费用。
Kidney360. 2023 Oct 1;4(10):1382-1388. doi: 10.34067/KID.0000000000000212. Epub 2023 Jul 18.
7
Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association.《心脏病与卒中统计数据-2023 更新:美国心脏协会报告》。
Circulation. 2023 Feb 21;147(8):e93-e621. doi: 10.1161/CIR.0000000000001123. Epub 2023 Jan 25.
8
Postdelivery Intervention to Prevent Type 2 Diabetes and the Cost-Effectiveness of Screening Criteria for Gestational Diabetes.产后干预预防 2 型糖尿病及妊娠期糖尿病筛查标准的成本效益分析。
Prev Chronic Dis. 2022 Dec 29;19:E89. doi: 10.5888/pcd19.220055.
9
Productivity Loss and Medical Costs Associated With Type 2 Diabetes Among Employees Aged 18-64 Years With Large Employer-Sponsored Insurance.18-64 岁有大型雇主赞助保险的员工中 2 型糖尿病导致的生产力损失和医疗费用。
Diabetes Care. 2022 Nov 1;45(11):2553-2560. doi: 10.2337/dc22-0445.
10
Effect of Fibroblast Growth Factor 21 on the Development of Atheromatous Plaque and Lipid Metabolic Profiles in an Atherosclerosis-Prone Mouse Model.成纤维细胞生长因子 21 对动脉粥样硬化易损小鼠模型动脉粥样硬化斑块形成和脂代谢特征的影响。
Int J Mol Sci. 2020 Sep 17;21(18):6836. doi: 10.3390/ijms21186836.
瑞典新诊断2型糖尿病后的医疗保健利用情况及费用:对临床实践环境中38956名患者的随访
Prim Care Diabetes. 2015 Oct;9(5):330-7. doi: 10.1016/j.pcd.2015.01.001. Epub 2015 Jan 24.
4
Increased cardiovascular disease, resource use, and costs before the clinical diagnosis of diabetes in veterans in the southeastern U.S.美国东南部退伍军人在糖尿病临床诊断之前心血管疾病增加、资源使用及成本上升
J Gen Intern Med. 2015 Jun;30(6):749-57. doi: 10.1007/s11606-014-3075-7. Epub 2015 Jan 22.
5
Change in medical spending attributable to diabetes: national data from 1987 to 2011.糖尿病导致的医疗支出变化:1987 年至 2011 年的全国数据。
Diabetes Care. 2015 Apr;38(4):581-7. doi: 10.2337/dc14-1687. Epub 2015 Jan 15.
6
The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84).糖尿病相关并发症对医疗费用的影响:英国前瞻性糖尿病研究(UKPDS 84)的新结果。
Diabet Med. 2015 Apr;32(4):459-66. doi: 10.1111/dme.12647. Epub 2015 Jan 7.
7
Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.生活方式干预对糖耐量受损人群的心血管死亡率、全因死亡率和糖尿病发病率的影响:大庆糖尿病预防研究 23 年随访研究。
Lancet Diabetes Endocrinol. 2014 Jun;2(6):474-80. doi: 10.1016/S2213-8587(14)70057-9. Epub 2014 Apr 3.
8
Lifetime direct medical costs of treating type 2 diabetes and diabetic complications.治疗 2 型糖尿病和糖尿病并发症的终身直接医疗费用。
Am J Prev Med. 2013 Sep;45(3):253-61. doi: 10.1016/j.amepre.2013.04.017.
9
Medical costs associated with type 2 diabetes complications and comorbidities.与 2 型糖尿病并发症和合并症相关的医疗费用。
Am J Manag Care. 2013 May;19(5):421-30.
10
Economic costs of diabetes in the U.S. in 2012.2012 年美国糖尿病的经济成本。
Diabetes Care. 2013 Apr;36(4):1033-46. doi: 10.2337/dc12-2625. Epub 2013 Mar 6.